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Usefulness of pamidronate in severe secondary hyperparathy- parathyroidism and hypercalcemia. Although SHP can be
roidism in patients undergoing hemodialysis. controlled medically in most patients, if hypercalcemia is
Background. Although bisphosphonates have been widely present, medical management may be very difficult, andused to treat bone diseases characterized by increased bone
parathyroidectomy could be the unique alternative.resorption, there are limited data showing their possible use-
On the other hand, the demographics of these patientsfulness in patients on hemodialysis (HD) with secondary hyper-
parathyroidism. have progressively changed, with an increasing propor-
Methods. The aim of this study was to evaluate the efficacy tion of elderly persons with the associated higher risk of
and safety of pamidronate in HD patients affected by severe
osteoporosis, being included in dialysis therapy. Cer-secondary hyperparathyroidism and moderate hypercalcemia
tainly, hypercalcemia of osseous origin and osteoporosiswho were receiving intravenous calcitriol (Calcijex).
Results. In this prospective one-year, open-labeled study, 13 could be present in patients on hemodialysis affected by
patients (9 women/4 men) with a mean age of 64  9 years secondary hyperparathyroidism. Bisphosphonates, then,
and a mean time on dialysis of 94 61 months were evaluated. could be useful in managing serum calcium and pre-The inclusion criteria were: iPTH500 pg/mL, Ca11 mg/dL,
venting bone loss in these patients.P 6 mg/dL, and osteopenia (T-score 1 SD). Blood levels
Pamidronate is a bisphosphonate that has been studiedof Ca, P, alkaline phosphatase (AP), and iPTH were assessed
at the beginning of the study and every month. Radiographs and shown to be well tolerated and beneficial in the
of the vertebral spine and bone mineral density (BMD) (lum- treatment of hypercalcemia [2], osteoporosis, steroid-
bar spine and femoral neck) were assessed basal and every 6
induced osteoporosis, and primary hyperparathyroidismmonths. All patients received 60 mg of pamidronate intrave-
[3]. The parenteral form of pamidronate has shown tonously every two months throughout the study period.
Calcitriol and phosphate binders were adjusted according to be well tolerated in doses up to 90 mg/day in adults [2].
iPTH, Ca, and P blood levels. BMD increased in both the However, limited data on pamidronate’s effects in di-
lumbar and femoral neck scans (mean increase of 33%) at 6 alysis patients are available at present.and 12 months. iPTH increased at 3 months in all patients, and
The aim of this study was to evaluate the efficacy anddecreased more than 50% in 10 patients after increasing the
safety of pamidronate in patients on HD affected by severecalcitriol doses. Three patients had no response. A slight de-
crease in Ca and P was observed in all patients with no signifi- secondary hyperparathyroidism and moderate hypercal-
cant changes in AP. There were no adverse events. cemia receiving several doses of intravenous calcitriol.
Conclusion. Pamidronate is effective in controlling hyper-
calcemia in patients on HD with secondary hyperparathyroid-
ism and allows for a more aggressive use of intravenous calcitriol. METHODS
In this prospective one-year, open-labeled study, thir-
teen patients (9 females and 4 males) on hemodialysis,Bisphosphonates are potent antiresorptive agents used
with a mean age of 64  9 years (range, 54 to 78), andto treat a variety of bone diseases that are characterized
a mean time on dialysis of 94 61 months, were enrolled.by increased bone resorption, including malignancy-as-
Primary renal diseases included polycystic kidney diseasesociated hypercalcemia [1].
in 4 cases; chronic pyelonephritis in 3 cases; chronic glo-Patients affected by renal insufficiency on hemodialy-
merulonephritis in 3 cases; nephroangioesclerosis in 1sis are at increased risk for developing secondary hyper-
case; and in 2 cases, the disease was unknown. Four
patients had previously experienced a renal graft rejec-
Key words: bisphosphonates, calcitriol, osteoporosis. tion and were returned to hemodialysis.
Inclusion criteria were the following: presence of a 2003 by the International Society of Nephrology
S-88
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Fig. 1. Bone mineral density evolution expressed as T-score.
persistent severe secondary hyperparathyroidism (de- Fig. 2. iPTH evolution (responders and non-responders) and calcitriol
dose throughout the study period.fined as a serum iPTH higher of 500 pg/mL), in addition
to a serum calcium level11 mg/dL and serum phospho-
rus level 6.5 mg/dL, and osteopenia (T-score 1 SD).
No patients had undergone parathyroidectomy, and pa- RESULTS
tients diagnosed of diabetes mellitus were excluded. The All patients completed the study. Bone mineral den-
study was conducted according to good clinical trial prac- sity changes are shown in Figure 1. As is seen, both
tice and the principles of the Declaration of Helsinki. areas (lumbar spine and femoral neck) were significantly
All patients gave their informed consent to the study. improved at the end of the study period (mean increase
All patients received pamidronate every two months of 33%) (P  0.01).
throughout the study period. Pamidronate was given in- Figure 2 illustrates the kinetics of serum iPTH and
travenously in dose of 60 mg during the hemodialysis calcitriol dose during the study period. Ten out of 13
session. Intravenous calcitriol (Calcijex) and phosphate patients (77%) showed a significant decrease in their
binders were administered according to the measured serum iPTH and were termed the “PTH-responder
iPTH, Ca, and P blood levels. group,” while the remaining three were termed the “PTH
Blood levels of calcium, phosphorus, alkaline phos- non-responder group.” A peak iPTH value was noticed
phatase, and iPTH were assessed at the beginning of the in all patients at three months of pamidronate therapy;
study and every month for one year. Radiographs of the nevertheless, in the responder group, with the increasing
vertebral spine and bone mineral density (lumbar spine of calcitriol dose, the iPTH value was completely re-
and femoral neck) were assessed basal and every six versed at six months, while at the end of the study, iPTH
months. values were significantly decreased (460  75 pg/mL)
During the study period the patients followed a dial- (P  0.001). Patients in the “non-responder group” dis-
ysis schedule of four hours per session three times a closed no significant changes in their iPTH serum levels
week with no changes in the dialysate Ca concentration (P  NS), despite the increased calcitriol dose.
(1.5 mmol/L). iPTH was measured by an intact-PTH The mean calcitriol dose was 1 g/week at the begin-
immunoradiometric assay (IRMA; Nichols Institute Di- ning of the study, 6 g/week at three months, and 3 g/
agnostics, San Diego, CA, USA), with a normal range week from 6 months to the end of the study.
between 12 and 65 pg/mL. Serum Ca, P, and alkaline A slight drop in serum calcium and phosphorus levels
phosphatases were measured using standard methodol- was detected in both groups simultaneously (Fig. 3), with
ogy. Bone mineral density was measured with a dual no significant changes in alkaline phosphatase.
energy x-ray absorptiometer (Lunar DPX-L, Lunar Ra- There were no adverse events during or after the pami-
diation Corp., Madison, WI, USA). Scans were made of dronate infusion. No fractures were observed during the
four lumbar vertebrae (L1 to L4) and the right proximal study period, assessed by radiographs of the vertebral
femur. The results were expressed as g/cm2 and derived spine.
by dividing the bone mineral content of hydroxyapatite
of each region by the projected bone area.
DISCUSSIONData were analyzed using the SPSS 10.0 statistical
package (SPSS, Inc., Chicago, IL, USA). Quantitative The present study shows that pamidronate is capable
variables are expressed as mean and standard error of of controlling hypercalcemia and osteopenia secondary
the mean. Analysis of variance (ANOVA) was used to to high bone turnover hyperparathyroidism in patients
assess the differences between variables. P  0.05 was on HD, providing a better optimization of calcitriol man-
agement in these patients.considered statistically significant.
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crease serum calcium concentrations with a compensa-
tory increase in PTH secretion, as was seen in our study.
The increased dose of calcitriol permitted control of
this increase in iPTH secretion and was able to posteri-
orly normalize it with a non-hypercalcemic effect.
CONCLUSION
Bisphosphonates represent potentially useful tools in
dialysis patients with severe secondary hyperparathy-
roidism. Therapy with intravenous pamidronate is ef-
fective in controlling hypercalcemia and allows a more
aggressive use of calcitriol, while at the same time dra-
Fig. 3. Ca and P blood levels throughout the study period. R is the matically improves the bone mineral density.
PTH responder group and Non-R is the PTH non-responder group. In patients on HD, further studies are needed to deter-
mine the best bisphosphonates, the optimal dose, the
frequency of administration, and when to stop them in
order to prevent bone loss and to obtain a better controlThe combination of high bone turnover hyperparathy-
of secondary hyperparathyroidism. This will enlarge the
roidism and the therapy with pamidronate had a rapid
therapeutic window for administration of vitamin D de-
effect on the amelioration of bone mineral density. rivatives.
Bisphosphonates are stable pyrophosphate analogs
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